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Abstract. Thyrotropin releasing hormone (TRH) was ad- 
ministered intravenously to ten patients with Alzheimer's 
Disease (AD) in a high-dose paradigm, thought to maxi- 
mize central nervous system effects and potentially produce 
facilitation of cholinergic function, a known property of 
the neuropeptide. Acute effects of TRH on behavioral, cog- 
nitive and physiologic measures were assessed after patients 
received 0.1 mg/kg TRH, 0.3 mg/kg TRH and placebo, the 
higher TRH dose and placebo being given in a randomized, 
double-blind fashion. Patients showed statistically signifi- 
cant increases in arousal and improvement in affect, as well 
as a modest improvement in semantic memory, all after 
receiving the higher TRH dose. Both TRH doses produced 
transient rises in systolic blood pressure, with no effect on 
diastolic blood pressure, heart rate or temperature. This 
study suggests that high-dose TRH can be safely admin- 
istered to AD patients and is neurobehaviorally active; fur- 
ther studies are needed to determine the extent and mecha- 
nism of the cognitive and psychobiological properties of 
this peptide in AD and other neuropsychiatric disorders. 
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In addition to its role in the regulation of thyroid function, 
thyrotropin releasing hormone (TRH) has long been recog- 
nized as a modulatory neuropeptide, with a broad spectrum 
of central nervous system (CNS) activity (Griffiths 1985; 
Horita et al. 1986). Abundant extra-hypothalamic TRH re- 
ceptors have been demonstrated in both rodent (Pazos et al. 
1985) and human brain (Manaker et al. 1986), and while 
considerable animal data has accumulated concerning the 
brain effects of TRH, little is known of the central conse- 
quences of TRH action in humans. Although TRH interacts 
with several classical neurotransmitters, the most robust 
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evidence is for a positive modulatory effect of TRH on 
the action of acetylcholine (Ach) in the CNS (Breese et al. 
1975; Yarbrough 1976; Schmidt 1977; Yarbrough and 
Singh 1977; Kalivas and Horita 1980; Pirola et al. /983; 
Yarbrough 1983). Alzheimers Disease (AD) is a neuropsy- 
chiatric disorder characterized clinically by progressive de- 
mentia; a prominent neurochemical feature of the illness 
is a loss of cortical markers for presynaptic Ach and a 
degeneration of cholinergic pathways; such cholinergic loss 
appears to correlate with clinical severity of the dementia 
(Davies and Maloney /976; Whitehouse et al. 1982; Sims 
et al. 1983). In addition, TRH levels have been reported 
to be decreased in the cerebrospinal fluid of dementia pa- 
tients (Oram et al. 1981), although not in post-mortem 
brain tissue (Yates et al. 1983). Because of its known posi- 
tive neuromodulatory effects on cholinergic transmission, 
we chose to examine, in a pilot fashion, the acute behavior- 
al, cognitive and physiologic effects of TRH in a group 
of patients with AD in an effort to explore whether a 'neu- 
romodulatory '  strategy was feasible in this illness, as has 
previously been suggested (Yarbrough and Pomara 1985). 
TRH has been reported to have antidepressant proper- 
ties (Kastin et al. 1972; Prange et al. 1972) and to be benefi- 
cial in schizophrenia (Wilson et al. 1973a; Inanaga et al. 
1978); these results have not been consistently replicated 
and remain controversial (Davis et al. 1975; van den Burg 
et al. 1976). A major limitation of previous psychopharma- 
cologic studies with TRH, including one small study with 
AD patients (Peabody et al. 1986), has been the use of doses 
which, although high enough to maximally stimulate pitui- 
tary function, are probably too low to gain sufficient CNS 
access to produce neurobehavioral effects (Nagai et al. 
1980; Sunderland et al. 1986). TRH is extremely labile in 
the circulation (Bassiri and Utiger 1973), owing to active 
enzymatic degradation (Redding and Schally 1969). Animal 
studies suggest that the doses required to produce behavior- 
al effects are 10-100 times higher than those which maxi- 
mally evoke thyroid stimulating hormone (TSH) release 
(Metcalf 1982). In this pilot study, therefore, we have ad- 
ministered TRH in intravenous doses up to 40 times those 
given previously in psychopharmacologic and endocrine 
studies of psychiatric patients, in hopes of achieving suffi- 
cient brain levels to observe central effects of TRH. A pre- 
liminary version of this work has been previously reported 
in abstract form (Mellow et al. 1987). 
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Methods 
Ten patients (five males, five females; mean age 64.3_+ 
2.2 years) were studied while inpatients on the N I M H  Unit  
on Geriatric Psychopharmacology. All patients met DSM- 
I I I -R criteria for Primary Degenerative Dementia of  the 
Alzheimer Type (American Psychiatric Association 1987) 
as well as N I N C D S - A D R D A  criteria for "probable" Alz- 
heimer's Disease (McKhann et al. 1984). Mean duration 
of  illness was 4.1 + 0.5 years and the mean Global Deterio- 
ration Scale (Reisberg etal.  1982) severity index was 
4.6__ 0.3, indicating moderate dementia. Patients were with- 
out serious medical illness or coexistent psychiatric dis- 
order, and had received no psychoactive drugs for at least 
3 weeks prior to the study. Patients underwent 3 separate 
study days (at least 72 h apart) as follows: On day 1, every 
patient received TRH,  0.1 mg/kg, under single-blind condi- 
tions. On days 2 and 3, patients received TRH,  0.3 mg/kg 
or placebo, in a randomized fashion. Both patients and 
physician-investigator were blind to drug/placebo condi- 
tions on days 2 and 3. The first day of  single-blind infusion 
was included, since the safety of  high doses of  T R H  in 
this population had not been established; an initial dose 
of  0.1 mg/kg was chosen to detect patients who might have 
unusuM sensitivity to the peptide. Every patient completed 
all 3 days of  the protocol. 
After an overnight fast, T R H  or saline placebo was ad- 
ministered through an inwelling intravenous catheter as a 
bolus infusion over 1 min. Behavioral measures were made 
30 min prior to drug infusion and 30 and 90 min after infu- 
sion and included: (1) Brief Psychiatric Rating Scale 
(BPRS; Overall and Gorham 1962), (2) an observer-rated 
100 mm Visual Analog Scale (VAS) for assessment of  
arousal, affect, motor  behavior, orientation and verbal ex- 
pression, designed to assess potential behavioral effects of  
cholinergic enhancement (Tariot et al. 1988), and (3) Modi- 
fied N I M H  Self-Rating Scale (van Kammen and Murphy 
1975). The cognitive battery was administered along with 
the behavioral ratings and included: (1) vigilance task (mea- 
sure of  attention) - patients were read a list of  18 words, 
of  which 6 were read once and 6 read twice, and were 
asked to note any repeated word;  (2) category retrieval 
(measure of  semantic or "knowledge"  memory) - patients 
were asked to generate related words over a 90-s period 
in response to a category stimulus (B/ittig and Montague 
1969; Tariot et al. 1988); (3)picture recognition task (mea- 
sure of  visual memory) - patients were shown ten simple 
pictures and, after a distractor task, shown the original 
pictures interspersed with ten new pictures and asked to 
identify old and new pictures; (4) Buschke selective remind- 
ing task (Buschke 1973) (measure of  episodic verbal memo- 
ry) - this task was modified for use with AD patients by 
decreasing the test word list from 12 to 6 words (Sunderland 
et al. 1987). Two patients were unable to complete the cog- 
nitive battery due to the severity of  their dementia at base- 
line; cognitive measures are reported for the remaining 
eight patients. Blood pressure and heart rate were measured 
at 5-min intervals using an automated vital signs monitor  
(Critikon Inc., Tampa,  FL), and oral temperature was mea- 
sured at 30-min intervals. 
Data  were analyzed with SAS statistical software (Cary, 
NC) by analysis of  variance (ANOVA) with repeat mea- 
sures; Pearson product-moment  correlation coefficients 
were calculated for correlation of  behavioral with physio- 
logic data. Analyses were done without regard to order 
of  drug presentation. Post hoc paired t-tests were performed 
on difference scores when the overall A N O V A  showed an 
interaction (difference scores are reported for clarity of  pre- 
sentation; ANOVAs  revealed no significant baseline differ- 
ences across treatment conditions). Significance was at the 
P =  0.05 level. T R H  was purchased from Peninsula Labora-  
tories (Belmont, CA) and analyzed for purity with high 
pressure liquid chromatography by the N I H  Pharmaceuti- 
cal Development Service. 
Results 
Physical effects. All patients tolerated the infusions without 
major adverse reactions. Most  experienced transient shiver- 
ing, urinary urgency and hot  and cold cutaneous sensations, 
which lasted about  5 rain, primarily after receiving the high- 
er T R H  dose. No  patients experienced nausea or vomiting. 
Behavioral measures. The results of  the behavioral measure- 
ments are summarized in Table 1. In the majority of  in- 
stances, when a significant behavioral effect occurred, it 
was detected by ratings obtained 30 min after drug infusion. 
The observer-rated Visual Analog Scales (VAS, Table 1 A) 
Table 1. Behavioral effects of high-dose TRH infusions in AD pa- 
tients (n = 10). Patients were rated 30 min before and 30 and 90 min 
after drug/placebo infusions. Each value represents mean_+SEM 
for the maximal change from baseline measurement for each treat- 
ment condition. P values refer to post hoc paired t-tests on differ- 
ence scores for those conditions showing an interaction on the 
ANOVA. In the majority of instances, maximum changes were 
detected by ratings obtained 30 min after drug infusion. 
A 
Placebo TRH (0.1) TRH (0.3) 
"Flushing" 0.3-+1.7 1 .9_+2 .2  0.0_+2.0 
"Motor Activation" 5 . 2 _ + 2 . 5  3 . 7 _ + 4 . 0  9.5_+3.1 b 
"Affect" 3.3_+4.2 2 .1_+5 .0  14.3-+3.3" 
"Arousal" 1.6_+3.0 0 ,2_+4 .8  13.0-+5,9 ~ 
"Orientation" 0.2+5.5 5,7-+ 6.7 1.8-+5.1 
"Expression" 1.3_+2.1 4.2_+2.6 -0.9_+2.5 
B 
Placebo TRH (0.1) TRH (0.3) 
"Activation-Euphoria" 1.8 • 1.8 5.0 i 2.6 9.8 + 4.3 c 
"Altered Self" 0.2+_0.6 -1.5_+0,7 0.8_+1.1 
"Anxiety" 1.5+3.5 7 . 2 _ + 5 . 2  4.0-+1.8 
"Depressed Affect" 1.0+2.2 -0.8_+2.8 -0.5_+3.3 
"Dysphoria" 0.0_+2.5 1.0___1.4 2.3-+1.6 
"Functional Deficit" 0.6+6.7 - 3.0-+ 3,9 5.3-+6.3 
" Significant difference from placebo (P<0.05). b Trend for differ- 
ence from placebo (P<0.15). c Significant change from baseline 
(P<0.02) 
A Effects on Visual Analog Scale (VAS) ratings. Patients were 
rated by a physician-investigator on six behavioral factors, each 
measured on a 100 mm line continuum. 
B Effects on NIMH Self-Ratings. Patients provided self-ratings on 
a 24-item questionaire covering various subjective mental states, 
rated from 0 (not present) to 10 (present in extreme). Subscale 
analysis of these data yields six behavioral parameters, each with 
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Fig. l. Effect of high-dose (0.3 mg/kg) TRH infusion on systolic 
blood pressure (SBP) in AD patients (n=9). Blood pressure was 
measured with an automated cuff system (Critikon) at five minute 
intervals. ** P<0.01, * P<0.05, different from placebo. A smaller, 
but significant rise in SBP was seen after infusion of TRH, 0.1 rag/ 
kg (graph not shown see text). - - n - -  TRH, 0,3 mg/kg; 
- - o - -  placebo 
showed a significant drug effect (P<0.05) for an increase 
in positive affect and an increase in arousal when patients 
received the higher (0.3 mg/kg) TRH dose. There was also 
a significant increase in motor activation (compared to ba- 
seline) after the higher dose. These objective behavioral 
changes were also reflected in a small increase in the self- 
rating score for the "Activation-Euphoria" subscale on the 
N I M H  Self-Rating Scale (Table 1 B). Overall BPRS scores 
did not change significantly with either drug dose; however, 
a subscale analysis of the BPRS showed a trend increase 
in the "Man ia "  score with the 0.3 mg/kg dose of TRH 
compared to placebo (data not shown). 
Cognitive measures. No effects of TRH infusions were no ted  
on measures of attention (vigilance task), episodic memory 
(Buschke task) or visual memory (picture recognition task). 
There was, however, a statistically significant drug-placebo 
difference in semantic memory as measured by category 
retrieval. The 0.3 mg/kg dose of TRH showed a drug-pla- 
cebo difference of 3.8 + 1.2 words, in the direction of im- 
provement on drug (P<0.02), a 34% difference in change 
from baseline. 
Physiologic measures. TRH produced significant, early, 
transient systolic blood pressure (BP) elevations at both 
doses. The means _+ SEM of the maximum rise over baseline 
in m m H g  were as follows: placebo: 5.1+2.6; TRH, 
0.I mg/kg: 13.4_+4.2 (P<0.05 different from placebo); 
TRH, 0.3 mg/kg: 23.4___3.9 (P<0.01 different from pla- 
cebo). The BP response to the higher TRH dose is depicted 
in Fig. I. There were no significant effects of TRH infusions 
on diastolic BP, temperature, or heart rate. There were also 
no significant correlations between peak change in systolic 
BP and any behavioral or cognitive measures. 
Discussion 
This study represents the first attempt to examine the effects 
of the neuropeptide thyrotropin releasing hormone in AD 
patients, using an acute infusion paradigm with doses we 
believe to be high enough to directly affect CNS function. 
TRH produced a small, acute improvement in mood and 
increase in arousal and motor activity. One drawback of the 
current study is the"  blindedness" of the design, since many 
of the patients experienced physical side-effects during ac- 
tive drug infusion. However, several patients had little recall 
of side-effects during subsequent rating, yet still developed 
increased arousal, so we believe this phenomenon to reflect 
a true drug effect. Furthermore, the effects are consistent 
with those seen in animal studies where TRH can increase 
locomotor activity (Miyamoto and Nagawa 1977; Masser- 
ano and King 1981), as well as in human studies, in which 
TRH, at lower doses, produced a mild euphoric response 
(Wilson et al. 1973b, 1980). The mechanisms for these find- 
ings are incompletely understood, although it has been sug- 
gested that the augmentation of locomotor activity is dopa- 
minergically mediated (Horita et al. 1986) and the effects 
on arousal may be related to the so-called "analeptic" 
properties of TRH (Metcalf and Dettmar 1981), with a 
cholinergic component being prominent (Kalivas and Hor- 
ita 1980). They are unlikely to be due to stimulation of 
the thyroid axis, since effects can be seen in hypophysecto- 
mized animals (Breese et al. 1975). Moreover, the euphor- 
iant effect of low-dose TRH in humans appears to be nega- 
tively correlated with plasma TSH response (Wilson et al. 
1973b, 1980), and high doses of TRH do not appear to 
further stimulate pituitary TSH release in animals (Metcalf 
1982) or humans (Mellow, unpublished observations). 
The modest cognitive effects of TRH in this study are 
difficult to interpret; improvement in word generation may 
be due only to the arousing effects of the drug or to a 
selective effect on semantic memory function, since mea- 
sures of attention were unaffected. This study examined 
only acute effects of the peptide, and it is possible that 
with chronic administration, more substantial effects on 
cognition might be observed. For example, in a recent 
study, Brambilla et al. (1986), demonstrated some cognitive 
improvement in chronic schizophrenics given daily, low- 
dose TRH infusions. Finally, it may be that the neurochem- 
ical lesions in AD preclude facilitation of cholinergic func- 
tion; alternatively, the doses used in the present study may 
be just at or below the threshold for major cognitive effects. 
In a recent study from our group (Molchan et al. 1988), 
TRH, at doses even higher than the present study, partially 
reversed the impairment in new learning induced by the 
anticholinergic drug scopolamine in normal controls; under 
these circumstances, when the underlying cholinergic sys- 
tems are intact, TRH may have positive modulatory effects 
on memory. 
The systolic blood pressure changes seen after TRH in- 
fusions in this study are similar in time course and magni- 
tude to those found by Borowski et al. (1984) after 500 gg 
TRH infusions in a large group of euthyroid patients. A 
similar rise in blood pressure was also seen by Mitsumoto 
et al. (1986) during continuous high-dose infusion of TRH 
to patients with amyotrophic lateral sclerosis. The precise 
mechanism of the pressor effect of TRH is unknown, al- 
though it is thought to involve central stimulation of the 
sympathetic nervous system (Horita et al. 1986). The lack 
of correlation of BP changes with behavioral/cognitive 
changes in this study suggests the possibility of separate 
mechanisms. It is of interest that we found no significant 
rise in diastolic BP; in a recent study, the diastolic BP re- 
sponse to TRH in AD patients was significantly blunted 
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compared  with age-matched controls  (T.H. Lampe,  per- 
sonal communicat ion).  In light of  recent evidence for a 
cholinergic component  to the T R H  pressor effect (Okuda 
et al. 1987), these and our own findings might be a reflection 
of  central cholinergic deficits in AD.  
In conclusion, in this pi lot  study, high-dose intravenous 
T R H  could be administered safely to A D  patients.  The 
behavioral  and  physiologic changes seen were similar to 
those found in earlier studies with much lower doses in 
normal  controls. I t  remains to be determined whether even 
higher doses will produce more pronounced or quali tat ively 
different findings, since the doses used in the present study 
may  only be at the threshold for significant central action 
(Metcalf  1982). Cognitive changes were minimal,  but  sug- 
gested a small, positive effect on semantic memory.  Fur ther  
work  is needed with this and  other  pat ient  populat ions ,  
as well as with normal  controls, to determine the parameters  
of  dosage as well as the extent and mechanisms of  the psy- 
chobiological  actions of  T R H  in humans.  Finally,  the pres- 
ent study provides a basis for further investigations into 
the role of  this neuropept ide in the possible pharmacologi -  
cal t reatment  of  the behavioral  changes seen in AD.  
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